Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 700 shares, an increase of 600.0% from the September 15th total of 100 shares. Based on an average daily trading volume, of 14,500 shares, the short-interest ratio is presently 0.0 days.

Shares of Clinuvel Pharmaceuticals stock traded up $0.47 on Thursday, reaching $28.69. 2,715 shares of the company were exchanged, compared to its average volume of 6,861. The company’s 50-day moving average is $26.22 and its two-hundred day moving average is $23.42. Clinuvel Pharmaceuticals has a 1-year low of $13.61 and a 1-year high of $31.44.

The business also recently disclosed a dividend, which was paid on Monday, September 27th. Investors of record on Monday, September 6th were given a $0.0181 dividend. This represents a yield of 0.07%. The ex-dividend date was Friday, September 3rd.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Further Reading: Investing in Blue-Chip Stocks

Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.